Sage Therapeutics, Inc. (NASDAQ:SAGE) is on our radar right now but there could still be some opportunities on the horizon. Now trading with a market value of 8.17B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.Sage Therapeutics, Inc. (NASDAQ:SAGE) Fundamentals That Matter
It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For SAGE, the company currently has 557.56 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 1.1 billion in total assets, balanced by 41.38 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.
Sage Therapeutics, Inc. (SAGE) saw -79.22 million in free cash flow last quarter, representing a quarterly net change in cash of 251.74 million. Perhaps most importantly where cash movements are concerned, the company saw about -78.57 million in net operating cash flow.
But what about the bottom line? After all, that’s what really matters in the end. Sage Therapeutics, Inc. (SAGE) is intriguing when broken down to its core data. The cost of selling goods last quarter was 247,000, yielding a gross basic income of -247,000 . For shareholders, given the total diluted outstanding shares of 44.33 million, this means overall earnings per share of -1.68. Note, this compares with a consensus analyst forecast of -2.18 in earnings per share for its next fiscal quarterly report.Is Sage Therapeutics, Inc. (NASDAQ:SAGE) Valuation Attractive
Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -9.52 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Sage Therapeutics, Inc..